Answers are grounded in this paper and cite their sources.
Assessment of the effectiveness, safety and tolerability of Ocrelizumab in the treatment of patients with Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in Southeastern Ontario.
No takes yet. Share an insight, caveat, or question.
Aljaser et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: